Dianthus Therapeutics, Inc. /DE/ (DNTH)
D
Pipeline Grade
Financial Position (from SEC Filings)
$627.8M
Cash & Equivalents
$28.9M
Quarterly Burn Rate
65 mo
Est. Cash Runway
$4,738M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05800509 | Gestational Diabetes and Perinatal Depression: an Intervention Program | OTHER | Recruiting | 600 |
| NCT06858579 | A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy ... | PHASE3 | Recruiting | 256 |
| NCT06282159 | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) | PHASE2 | Active Not Recruiting | 65 |
| NCT06537999 | A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy | PHASE2 | Recruiting | 36 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.